$TGTX
TG THERAPEUTICS, INC.

2020 Q1 Form 10-K Financial Statement

#000155837020001897 Filed on March 02, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q4 2019 Q3
Revenue $38.00K $40.00K $38.00K
YoY Change 0.0% 0.0% 0.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $14.26M $7.060M $2.910M
YoY Change 509.44% 269.63% 200.0%
% of Gross Profit
Research & Development $36.02M $30.94M $57.99M
YoY Change 11.23% -40.82% 73.62%
% of Gross Profit
Depreciation & Amortization $30.00K $30.00K $20.00K
YoY Change 30.43% 0.0% 0.0%
% of Gross Profit
Operating Expenses $50.28M $38.00M $60.90M
YoY Change 44.8% -29.88% 77.21%
Operating Profit -$50.25M -$60.86M
YoY Change 44.84% 77.29%
Interest Expense $1.201M -$1.900M $1.537M
YoY Change 55.17% -803.7% 595.48%
% of Operating Profit
Other Income/Expense, Net -$871.0K $290.0K -$1.069M
YoY Change 86.51% 1350.0% 183.55%
Pretax Income -$51.12M -$39.57M -$61.93M
YoY Change 45.39% -26.53% 82.42%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$51.12M -$39.57M -$61.93M
YoY Change 45.4% -26.53% 82.41%
Net Earnings / Revenue -134515.79% -98927.5% -162973.68%
Basic Earnings Per Share
Diluted Earnings Per Share -$484.7K -$413.3K -$690.6K
COMMON SHARES
Basic Shares Outstanding 109.4M 99.56M shares 94.76M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q4 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $78.30M $140.4M $72.50M
YoY Change -15.35% 104.07% -25.79%
Cash & Equivalents $52.05M $112.6M $44.68M
Short-Term Investments $26.30M $27.80M $27.80M
Other Short-Term Assets $1.944M $611.0K $864.0K
YoY Change -84.57% 39.18% -92.74%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $88.02M $149.2M $80.36M
YoY Change -16.25% 88.72% -26.75%
LONG-TERM ASSETS
Property, Plant & Equipment $320.0K $282.0K $275.0K
YoY Change -96.92% 12.35% -89.42%
Goodwill $799.0K $799.0K $799.0K
YoY Change 0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.300M $1.300M $1.200M
YoY Change 8.33% 8.33% 0.0%
Total Long-Term Assets $13.83M $13.86M $12.97M
YoY Change 11.56% 202.36% 176.0%
TOTAL ASSETS
Total Short-Term Assets $88.02M $149.2M $80.36M
Total Long-Term Assets $13.83M $13.86M $12.97M
Total Assets $101.8M $163.0M $93.33M
YoY Change -13.32% 94.96% -18.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $30.90M $30.00M $31.80M
YoY Change -23.13% -17.58% -16.09%
Accrued Expenses $3.000M $5.400M $4.400M
YoY Change 42.86% 134.78% 109.52%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $200.0K $0.00 $0.00
YoY Change 100.0% -100.0% -100.0%
Total Short-Term Liabilities $63.12M $84.45M $80.20M
YoY Change 3.64% 117.35% 99.5%
LONG-TERM LIABILITIES
Long-Term Debt $29.20M $28.97M $28.74M
YoY Change 3.18%
Other Long-Term Liabilities $10.90M $0.00 $0.00
YoY Change 19.78% -100.0% -100.0%
Total Long-Term Liabilities $29.20M $28.97M $28.74M
YoY Change -21.92% 57.87% 1097.54%
TOTAL LIABILITIES
Total Short-Term Liabilities $63.12M $84.45M $80.20M
Total Long-Term Liabilities $29.20M $28.97M $28.74M
Total Liabilities $103.2M $124.4M $119.1M
YoY Change 4.99% 108.79% 179.62%
SHAREHOLDERS EQUITY
Retained Earnings -$752.3M -$701.2M -$661.6M
YoY Change 32.72%
Common Stock $110.0K $109.0K $97.00K
YoY Change 29.76%
Preferred Stock
YoY Change
Treasury Stock (at cost) $234.0K $234.0K $234.0K
YoY Change 0.0%
Treasury Stock Shares $41.31K $41.31K 41.31K shares
Shareholders Equity -$1.400M $38.60M -$25.80M
YoY Change
Total Liabilities & Shareholders Equity $101.8M $163.0M $93.33M
YoY Change -13.32% 94.96% -18.42%

Cashflow Statement

Concept 2020 Q1 2019 Q4 2019 Q3
OPERATING ACTIVITIES
Net Income -$51.12M -$39.57M -$61.93M
YoY Change 45.4% -26.53% 82.41%
Depreciation, Depletion And Amortization $30.00K $30.00K $20.00K
YoY Change 30.43% 0.0% 0.0%
Cash From Operating Activities -$62.12M -$30.40M -$33.20M
YoY Change 86.25% -9.77% 0.58%
INVESTING ACTIVITIES
Capital Expenditures $68.00K -$30.00K -$70.00K
YoY Change 385.71% 200.0% 250.0%
Acquisitions
YoY Change
Other Investing Activities $1.520M $40.00K $20.00K
YoY Change -235.71% -83.33% -100.31%
Cash From Investing Activities $1.450M $0.00 -$40.00K
YoY Change -227.75% -100.0% -99.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $50.00M
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 81.00K 98.35M 20.70M
YoY Change -99.86% 1997.01% 360.0%
NET CHANGE
Cash From Operating Activities -62.12M -30.40M -33.20M
Cash From Investing Activities 1.450M 0.000 -40.00K
Cash From Financing Activities 81.00K 98.35M 20.70M
Net Change In Cash -60.58M 67.95M -12.54M
YoY Change -370.54% -336.27% -64.12%
FREE CASH FLOW
Cash From Operating Activities -$62.12M -$30.40M -$33.20M
Capital Expenditures $68.00K -$30.00K -$70.00K
Free Cash Flow -$62.18M -$30.37M -$33.13M
YoY Change 86.37% -9.83% 0.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
83911855
CY2019 dei Entity Central Index Key
EntityCentralIndexKey
0001001316
CY2019 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2019 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2019 dei Amendment Flag
AmendmentFlag
false
CY2019 dei Trading Symbol
TradingSymbol
TGTX
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0.0001
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
0.0001
CY2014Q3 tgtx Common Stock Years Before Rights Will Expire
CommonStockYearsBeforeRightsWillExpire
P10Y
CY2019 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y
CY2017Q1 tgtx Period Of Underwriter Overallotment Option
PeriodOfUnderwriterOverallotmentOption
P30D
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2019 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019 dei Document Type
DocumentType
10-K
CY2019 dei Document Annual Report
DocumentAnnualReport
true
CY2019 dei Document Period End Date
DocumentPeriodEndDate
2019-12-31
CY2019 dei Document Transition Report
DocumentTransitionReport
false
CY2019 dei Entity File Number
EntityFileNumber
1-32639
CY2019 dei Entity Registrant Name
EntityRegistrantName
TG THERAPEUTICS, INC.
CY2019 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2019 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
36-3898269
CY2019 dei Entity Address Address Line1
EntityAddressAddressLine1
2 Gansevoort St.
CY2019 dei Entity Address Address Line2
EntityAddressAddressLine2
9th Floor
CY2019 dei Entity Address City Or Town
EntityAddressCityOrTown
New York
CY2019 dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
CY2019 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10014
CY2019 dei City Area Code
CityAreaCode
212
CY2019 dei Local Phone Number
LocalPhoneNumber
554-4484
CY2019 dei Security12g Title
Security12gTitle
Common Stock, par value $0.001
CY2019 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
Yes
CY2019Q4 tgtx End Of Term Fee
EndOfTermFee
975000
CY2019Q4 tgtx Long Term Debt Gross
LongTermDebtGross
30975000
CY2019 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2019 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2019 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q2 dei Entity Public Float
EntityPublicFloat
687572082
CY2020Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
109401184
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112637000
CY2019 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2019 dei Entity Small Business
EntitySmallBusiness
false
CY2019 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2019 dei Entity Shell Company
EntityShellCompany
false
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41958000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
27798000
CY2018Q4 us-gaap Short Term Investments
ShortTermInvestments
26943000
CY2019Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
8105000
CY2018Q4 tgtx Prepaid Research And Development
PrepaidResearchAndDevelopment
9691000
CY2019Q4 us-gaap Other Assets Current
OtherAssetsCurrent
611000
CY2018Q4 us-gaap Other Assets Current
OtherAssetsCurrent
439000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
149151000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
79031000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
1251000
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
1241000
CY2019Q4 tgtx Leasehold Interest
LeaseholdInterest
2129000
CY2018Q4 tgtx Leasehold Interest
LeaseholdInterest
2294000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
282000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
251000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
9402000
CY2018Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
0
CY2019Q4 us-gaap Goodwill
Goodwill
799000
CY2018Q4 us-gaap Goodwill
Goodwill
799000
CY2019Q4 us-gaap Assets
Assets
163014000
CY2018Q4 us-gaap Assets
Assets
83616000
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
30041000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
36377000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
48994000
CY2018Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
219000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1616000
CY2019Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
3798000
CY2018Q4 us-gaap Deferred Compensation Liability Current
DeferredCompensationLiabilityCurrent
2258000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
84449000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
38854000
CY2019Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
0
CY2018Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
1462000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
762000
CY2018Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
914000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
28970000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10218000
CY2018Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
0
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2018Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
18350000
CY2019Q4 us-gaap Liabilities
Liabilities
124399000
CY2018Q4 us-gaap Liabilities
Liabilities
59580000
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2014Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
100.00
CY2018Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2018Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
109425243
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
109383934
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
83870546
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
109000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
84000
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
739956000
CY2018Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
552531000
CY2018Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
234000
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
234000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-701216000
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-528345000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
38615000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24036000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
163014000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83616000
CY2019 us-gaap Revenues
Revenues
152000
CY2018 us-gaap Revenues
Revenues
152000
CY2017 us-gaap Revenues
Revenues
152000
CY2019 tgtx Non Cash Stock Expense Associated With In Licensing Agreements
NonCashStockExpenseAssociatedWithInLicensingAgreements
100000
CY2018 tgtx Non Cash Stock Expense Associated With In Licensing Agreements
NonCashStockExpenseAssociatedWithInLicensingAgreements
4000000
CY2017 tgtx Non Cash Stock Expense Associated With In Licensing Agreements
NonCashStockExpenseAssociatedWithInLicensingAgreements
0
CY2019 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
5811000
CY2018 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
5598000
CY2017 tgtx Non Cash Compensation Research And Development Expenses
NonCashCompensationResearchAndDevelopmentExpenses
5647000
CY2019 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
148269000
CY2018 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
149793000
CY2017 us-gaap Other Research And Development Expense
OtherResearchAndDevelopmentExpense
96886000
CY2019 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
154180000
CY2018 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
159391000
CY2017 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
102533000
CY2019 tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
5523000
CY2018 tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
7288000
CY2017 tgtx Non Cash Compensation General And Administrative Expenses
NonCashCompensationGeneralAndAdministrativeExpenses
10298000
CY2019 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
9504000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-169055000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-174400000
CY2017 us-gaap Operating Income Loss
OperatingIncomeLoss
-118712000
CY2019 us-gaap Interest Expense
InterestExpense
5287000
CY2018 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
7873000
CY2017 us-gaap Other General And Administrative Expense
OtherGeneralAndAdministrativeExpense
6033000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15027000
CY2018 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15161000
CY2017 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
16331000
CY2019 us-gaap Operating Expenses
OperatingExpenses
169207000
CY2018 us-gaap Operating Expenses
OperatingExpenses
174552000
CY2017 us-gaap Operating Expenses
OperatingExpenses
118864000
CY2018 us-gaap Interest Expense
InterestExpense
877000
CY2017 us-gaap Interest Expense
InterestExpense
845000
CY2019 us-gaap Other Income
OtherIncome
1471000
CY2018 us-gaap Other Income
OtherIncome
1795000
CY2017 us-gaap Other Income
OtherIncome
1081000
CY2019 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3816000
CY2018 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
918000
CY2017 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
236000
CY2019 us-gaap Profit Loss
ProfitLoss
-172871000
CY2018 us-gaap Profit Loss
ProfitLoss
-173482000
CY2017 us-gaap Profit Loss
ProfitLoss
-118476000
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.96
CY2018 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.30
CY2017 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.91
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
88368844
CY2018 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
75466813
CY2017 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
62069570
CY2016Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
35868000
CY2017 tgtx Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
2142000
CY2017Q4 tgtx Offering Costs
OfferingCosts
3600000
CY2017 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
53640000
CY2017Q4 tgtx Offering Costs At Market
OfferingCostsAtMarket
1100000
CY2017 tgtx Issuance Of Common Stock In At Market Offering Net Of Offering Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts
77873000
CY2017 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
15945000
CY2017 us-gaap Profit Loss
ProfitLoss
-118476000
CY2017Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
66993000
CY2018Q4 tgtx Offering Costs At Market
OfferingCostsAtMarket
2000000.0
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
113639000
CY2018 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
12886000
CY2018 tgtx Stock Issued During Period Value In Licensing Agreements
StockIssuedDuringPeriodValueInLicensingAgreements
4000000
CY2018 us-gaap Profit Loss
ProfitLoss
-173482000
CY2018Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
24036000
CY2019 us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
993000
CY2019Q4 tgtx Offering Costs
OfferingCosts
200000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
77475000
CY2019Q4 tgtx Offering Costs At Market
OfferingCostsAtMarket
2000000.0
CY2019 tgtx Issuance Of Common Stock In At Market Offering Net Of Offering Costs
IssuanceOfCommonStockInAtMarketOfferingNetOfOfferingCosts
97547000
CY2019 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
11335000
CY2019 tgtx Stock Issued During Period Value In Licensing Agreements
StockIssuedDuringPeriodValueInLicensingAgreements
100000
CY2019 us-gaap Profit Loss
ProfitLoss
-172871000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
38615000
CY2019 us-gaap Profit Loss
ProfitLoss
-172871000
CY2018 us-gaap Profit Loss
ProfitLoss
-173482000
CY2017 us-gaap Profit Loss
ProfitLoss
-118476000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11335000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12886000
CY2017 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
15945000
CY2019 tgtx Shares Issued In Connection With In Licensing Agreement
SharesIssuedInConnectionWithInLicensingAgreement
100000
CY2018 tgtx Shares Issued In Connection With In Licensing Agreement
SharesIssuedInConnectionWithInLicensingAgreement
4000000
CY2017 tgtx Shares Issued In Connection With In Licensing Agreement
SharesIssuedInConnectionWithInLicensingAgreement
0
CY2019 us-gaap Depreciation
Depreciation
100000
CY2018 us-gaap Depreciation
Depreciation
88000
CY2017 us-gaap Depreciation
Depreciation
82000
CY2019 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
257000
CY2018 us-gaap Investment Income Amortization Of Discount
InvestmentIncomeAmortizationOfDiscount
119000
CY2017 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
61000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
772000
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
CY2017 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
CY2019 us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
182000
CY2018 us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
135000
CY2017 us-gaap Amortization Of Lease Incentives
AmortizationOfLeaseIncentives
125000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2519000
CY2018 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2017 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2019 tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
-124000
CY2018 tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
61000
CY2017 tgtx Change In Fair Value Of Notes Payable
ChangeInFairValueOfNotesPayable
-59000
CY2019 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-1395000
CY2018 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
1638000
CY2017 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
2665000
CY2019 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
11000
CY2018 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
-14000
CY2017 us-gaap Increase Decrease In Accrued Interest Receivable Net
IncreaseDecreaseInAccruedInterestReceivableNet
25000
CY2019 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2018 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
CY2017 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-162000
CY2019 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-4795000
CY2018 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
10957000
CY2017 us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
11020000
CY2019 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-1548000
CY2018 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
0
CY2017 us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
0
CY2019 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
1491000
CY2018 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0
CY2017 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
0
CY2019 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
0
CY2018 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-97000
CY2017 us-gaap Increase Decrease In Deferred Charges
IncreaseDecreaseInDeferredCharges
-104000
CY2019 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-152000
CY2018 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-152000
CY2017 us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
0
CY2019 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
28810000
CY2018 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
18350000
CY2017 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-152000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-132806000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-128925000
CY2017 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-93760000
CY2019 tgtx Proceeds From Maturities
ProceedsFromMaturities
29250000
CY2018 tgtx Proceeds From Maturities
ProceedsFromMaturities
32500000
CY2017 tgtx Proceeds From Maturities
ProceedsFromMaturities
19800000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43199000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57305000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
25614000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113888000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43199000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57305000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112637000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41958000
CY2019 tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
29837000
CY2018 tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
31230000
CY2017 tgtx Payments To Acquire Held To Maturity Securities Short Term
PaymentsToAcquireHeldToMaturitySecuritiesShortTerm
28006000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
131000
CY2018 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
90000
CY2017 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-718000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1180000
CY2017 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-8208000
CY2019 tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
175021000
CY2018 tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
113639000
CY2017 tgtx Net Proceeds From Shares New Issues Overallotments
NetProceedsFromSharesNewIssuesOverallotments
131516000
CY2019 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
29987000
CY2018 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
0
CY2017 us-gaap Proceeds From Other Debt
ProceedsFromOtherDebt
0
CY2019 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2018 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
0
CY2017 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
2143000
CY2019 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
795000
CY2018 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2017 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
0
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
204213000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
113639000
CY2017 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
133659000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
70689000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14106000
CY2017 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
31691000
CY2017Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
56718000
CY2019Q4 us-gaap Restricted Cash
RestrictedCash
1251000
CY2018Q4 us-gaap Restricted Cash
RestrictedCash
1241000
CY2017Q4 us-gaap Restricted Cash
RestrictedCash
587000
CY2019 tgtx Reclassification Of Deferred Financing Costs
ReclassificationOfDeferredFinancingCosts
0
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
113888000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
43199000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
57305000
CY2019 tgtx Accrued Financing Costs
AccruedFinancingCosts
988000
CY2018 tgtx Accrued Financing Costs
AccruedFinancingCosts
0
CY2017 tgtx Accrued Financing Costs
AccruedFinancingCosts
0
CY2019 tgtx Warrants Issued With Debt Financing
WarrantsIssuedWithDebtFinancing
993000
CY2018 tgtx Warrants Issued With Debt Financing
WarrantsIssuedWithDebtFinancing
0
CY2017 tgtx Warrants Issued With Debt Financing
WarrantsIssuedWithDebtFinancing
0
CY2019 tgtx Shares Issued In Connection With In Licensing Agreements Value
SharesIssuedInConnectionWithInLicensingAgreementsValue
100000
CY2018 tgtx Shares Issued In Connection With In Licensing Agreements Value
SharesIssuedInConnectionWithInLicensingAgreementsValue
4000000
CY2017 tgtx Shares Issued In Connection With In Licensing Agreements Value
SharesIssuedInConnectionWithInLicensingAgreementsValue
0
CY2018 tgtx Reclassification Of Deferred Financing Costs
ReclassificationOfDeferredFinancingCosts
0
CY2017 tgtx Reclassification Of Deferred Financing Costs
ReclassificationOfDeferredFinancingCosts
-3000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-701200000
CY2019Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
140400000
CY2019 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">USE OF ESTIMATES</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (“GAAP”) requires management to make estimates and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the applicable reporting period. On an ongoing basis, we evaluate our estimates and judgments, including those related to accrued expenses and stock-based compensation. Actual results could differ from those estimates. Such differences could be material to the financial statements.</p>
CY2018Q4 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
1300000
CY2019Q4 us-gaap Restricted Cash And Investments
RestrictedCashAndInvestments
1300000
CY2019 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman';font-size:10pt;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">CREDIT RISK</p><p style="font-family:'Times New Roman';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and short-term investments. The Company maintains its cash and cash equivalents and short-term investments with high-credit quality financial institutions. At times, such amounts may exceed federally-insured limits.</p>
CY2019Q4 tgtx Prepaid Manufacturing
PrepaidManufacturing
8100000
CY2018Q4 tgtx Prepaid Manufacturing
PrepaidManufacturing
9700000
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6528932
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4835706
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8361739
CY2018 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6528932
CY2017 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4835706
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8361739
CY2019 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2019Q4 us-gaap Cash
Cash
110135000
CY2018Q4 us-gaap Cash
Cash
39268000
CY2019Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
2502000
CY2018Q4 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
2690000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
112637000
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
41958000
CY2019Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
27798000
CY2019 tgtx Debt Securities Held To Maturity Unrealized Gain
DebtSecuritiesHeldToMaturityUnrealizedGain
28000
CY2019 tgtx Debt Securities Held To Maturity Unrealized Loss
DebtSecuritiesHeldToMaturityUnrealizedLoss
0
CY2019Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
27826000
CY2018Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
26943000
CY2018 tgtx Debt Securities Held To Maturity Unrealized Gain
DebtSecuritiesHeldToMaturityUnrealizedGain
2000
CY2018 tgtx Debt Securities Held To Maturity Unrealized Loss
DebtSecuritiesHeldToMaturityUnrealizedLoss
10000
CY2018Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
26935000
CY2019Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
190000
CY2019Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
190000
CY2018Q4 us-gaap Liabilities Fair Value Disclosure
LiabilitiesFairValueDisclosure
67000
CY2018Q4 us-gaap Notes Payable Fair Value Disclosure
NotesPayableFairValueDisclosure
67000
CY2018Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2014Q3 tgtx Number Of Days Rights Become Exercisable
NumberOfDaysRightsBecomeExercisable
P10D
CY2014Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
1
CY2019Q1 us-gaap Share Price
SharePrice
5.87
CY2019Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
27500000
CY2019Q1 tgtx Payments Of Underwriting Discounts And Offering Expenses
PaymentsOfUnderwritingDiscountsAndOfferingExpenses
200000
CY2019Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5434783
CY2019Q4 us-gaap Share Price
SharePrice
9.20
CY2019Q4 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
50000000.0
CY2018Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 tgtx Common Stock Commission Rate
CommonStockCommissionRate
0.030
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
5128206
CY2017Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
769230
CY2017Q1 us-gaap Share Price
SharePrice
9.75
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
54000000
CY2017Q1 tgtx Payments Of Underwriting Discounts And Offering Expenses
PaymentsOfUnderwritingDiscountsAndOfferingExpenses
3600000
CY2017Q2 tgtx Common Stock Commission Rate
CommonStockCommissionRate
0.030
CY2019Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
4100000
CY2019Q4 tgtx Remaining Common Stock Available For Sale
RemainingCommonStockAvailableForSale
9500000
CY2018Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2019Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
41309
CY2018Q4 us-gaap Treasury Stock Value
TreasuryStockValue
234000
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2605730
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1916900
CY2017Q1 tgtx Incremental Stock Based Compensation Expense
IncrementalStockBasedCompensationExpense
0
CY2018 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y9M
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y11M1D
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P8Y11M1D
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.7299
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
2.9161
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.9276
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
2.9671
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0182
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0249
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0249
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0256
CY2019 tgtx Warrant Or Right Exercised Weighted Average Exercise Price
WarrantOrRightExercisedWeightedAverageExercisePrice
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
0
CY2019 tgtx Warrant Or Right Expired Weighted Average Exercise Price
WarrantOrRightExpiredWeightedAverageExercisePrice
0
CY2019Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
147058
CY2019 tgtx Warrant Or Right Issued Weighted Average Exercise Price
WarrantOrRightIssuedWeightedAverageExercisePrice
4.08
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
7800000
CY2018 us-gaap Share Based Compensation
ShareBasedCompensation
12900000
CY2017 us-gaap Share Based Compensation
ShareBasedCompensation
15900000
CY2019Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
15300000
CY2016Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
913379
CY2016Q4 tgtx Warrant Or Right Outstanding Weighted Average Exercise Price
WarrantOrRightOutstandingWeightedAverageExercisePrice
2.41
CY2016Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
1961403
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
0
CY2017 tgtx Warrant Or Right Issued Weighted Average Exercise Price
WarrantOrRightIssuedWeightedAverageExercisePrice
0
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
887585
CY2017 tgtx Warrant Or Right Exercised Weighted Average Exercise Price
WarrantOrRightExercisedWeightedAverageExercisePrice
2.41
CY2017 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
25794
CY2017 tgtx Warrant Or Right Expired Weighted Average Exercise Price
WarrantOrRightExpiredWeightedAverageExercisePrice
0
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
0
CY2017Q4 tgtx Warrant Or Right Outstanding Weighted Average Exercise Price
WarrantOrRightOutstandingWeightedAverageExercisePrice
0
CY2017Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
0
CY2018 tgtx Warrant Or Right Issued Weighted Average Exercise Price
WarrantOrRightIssuedWeightedAverageExercisePrice
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
0
CY2018 tgtx Warrant Or Right Exercised Weighted Average Exercise Price
WarrantOrRightExercisedWeightedAverageExercisePrice
0
CY2018 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
0
CY2018 tgtx Warrant Or Right Expired Weighted Average Exercise Price
WarrantOrRightExpiredWeightedAverageExercisePrice
0
CY2018Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
0
CY2018Q4 tgtx Warrant Or Right Outstanding Weighted Average Exercise Price
WarrantOrRightOutstandingWeightedAverageExercisePrice
0
CY2018Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
0
CY2019 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
147058
CY2019Q4 tgtx Warrant Or Right Outstanding Weighted Average Exercise Price
WarrantOrRightOutstandingWeightedAverageExercisePrice
4.08
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
1032347
CY2017Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2018Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
0
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
190000
CY2019Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0
CY2019Q4 us-gaap Notes Payable
NotesPayable
190000
CY2018Q4 us-gaap Notes Payable Current
NotesPayableCurrent
67000
CY2018Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
0
CY2018Q4 us-gaap Notes Payable
NotesPayable
67000
CY2019 tgtx Cumulative Liability Of Note
CumulativeLiabilityOfNote
19300000
CY2018 tgtx Cumulative Liability Of Note
CumulativeLiabilityOfNote
18400000
CY2019 tgtx Agreement Costs Current Liabilities
AgreementCostsCurrentLiabilities
47200000
CY2019Q4 us-gaap Construction Contract Cost Progress Payment Offset
ConstructionContractCostProgressPaymentOffset
0
CY2019 tgtx Agreement Costs Current Liabilities
AgreementCostsCurrentLiabilities
47200000
CY2018 tgtx Agreement Costs Current Liabilities
AgreementCostsCurrentLiabilities
18400000
CY2019 tgtx Percentage Of Administrative Fee
PercentageOfAdministrativeFee
0.06
CY2019 tgtx Interest Expense Recognized As Administrative Fees
InterestExpenseRecognizedAsAdministrativeFees
1200000
CY2019Q4 tgtx Class Of Warrant Or Right Fair Value
ClassOfWarrantOrRightFairValue
1000000.0
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
800000
CY2019Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
2000000.0
CY2019Q4 us-gaap Other Long Term Debt
OtherLongTermDebt
30000000
CY2019Q4 us-gaap Unamortized Debt Issuance Expense
UnamortizedDebtIssuanceExpense
2005000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
28970000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
0
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
28970000
CY2019 us-gaap Operating Lease Cost
OperatingLeaseCost
2651000
CY2018 tgtx Operating Lease Cost Under Topic840
OperatingLeaseCostUnderTopic840
1440000
CY2019 us-gaap Lease Cost
LeaseCost
2651000
CY2018 tgtx Lease Cost Under Topic840
LeaseCostUnderTopic840
1440000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1616000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10218000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11834000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1804000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1874000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
1911000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
1913000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1796000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
10615000
CY2019Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
19913000
CY2019Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
8079000
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
11834000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
186711000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
142947000
CY2017 tgtx Tax Cuts And Jobs Act Change In Tax Rate Deferred Tax Asset Income Tax Expense
TaxCutsAndJobsActChangeInTaxRateDeferredTaxAssetIncomeTaxExpense
51767584
CY2019Q4 us-gaap Operating Loss Carryforwards
OperatingLossCarryforwards
709949000
CY2019Q4 tgtx Research And Development Carryforward
ResearchAndDevelopmentCarryforward
22483000
CY2019Q4 tgtx Business Interest Expense Carryforward
BusinessInterestExpenseCarryforward
3189000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
158177000
CY2018Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
122678000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
22483000
CY2018Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
15217000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
4680000
CY2018Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits
4394000
CY2019Q4 tgtx Deferred Tax Asset Disallowed Interest
DeferredTaxAssetDisallowedInterest
710000
CY2018Q4 tgtx Deferred Tax Asset Disallowed Interest
DeferredTaxAssetDisallowedInterest
0
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
661000
CY2018Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
658000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
186711000
CY2018Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
142947000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
186711000
CY2018Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
142947000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2018Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
0
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-172871000
CY2018 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-173482000
CY2017 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-118476
CY2019 us-gaap Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
-36303000
CY2018 us-gaap Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
-36431000
CY2017 us-gaap Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items
IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems
-40282
CY2019 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2128000
CY2018 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-2243000
CY2017 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-1106
CY2019 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
7266000
CY2018 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
4726000
CY2017 us-gaap Income Tax Reconciliation Tax Credits Research
IncomeTaxReconciliationTaxCreditsResearch
3697
CY2019 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
641000
CY2018 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
639000
CY2017 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
1563
CY2019 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
1292000
CY2018 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
-473000
CY2017 us-gaap Income Tax Reconciliation Nondeductible Expense Share Based Compensation Cost
IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
8213
CY2019 tgtx Effects Of Federal Tax Reform Rate Changes
EffectsOfFederalTaxReformRateChanges
0
CY2018 tgtx Effects Of Federal Tax Reform Rate Changes
EffectsOfFederalTaxReformRateChanges
0
CY2017 tgtx Effects Of Federal Tax Reform Rate Changes
EffectsOfFederalTaxReformRateChanges
51768
CY2019 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
43764000
CY2018 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
43234000
CY2017 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
-16459
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2018 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2017 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Contractual Obligation
ContractualObligation
97600000
CY2019Q4 us-gaap Contractual Obligation
ContractualObligation
97608000
CY2019Q4 us-gaap Contractual Obligation Due In Next Twelve Months
ContractualObligationDueInNextTwelveMonths
49499000
CY2019Q4 us-gaap Contractual Obligation Due In Second And Third Year
ContractualObligationDueInSecondAndThirdYear
33785000
CY2019Q4 us-gaap Contractual Obligation Due In Fourth And Fifth Year
ContractualObligationDueInFourthAndFifthYear
3709000
CY2019Q4 us-gaap Contractual Obligation Due After Fifth Year
ContractualObligationDueAfterFifthYear
10615000
CY2019 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2700000
CY2018 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1400000
CY2017 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1400000
CY2019Q1 tgtx License Revenues
LicenseRevenues
38000
CY2019Q2 tgtx License Revenues
LicenseRevenues
38000
CY2019Q3 tgtx License Revenues
LicenseRevenues
38000
CY2019Q4 tgtx License Revenues
LicenseRevenues
38000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
34727000
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
35582000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
60899000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
37998000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-35156000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-36213000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-61930000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-39571000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.44
CY2018Q1 tgtx License Revenues
LicenseRevenues
38000
CY2018Q2 tgtx License Revenues
LicenseRevenues
38000
CY2018Q3 tgtx License Revenues
LicenseRevenues
38000
CY2018Q4 tgtx License Revenues
LicenseRevenues
38000
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
41615000
CY2018Q2 us-gaap Operating Expenses
OperatingExpenses
44383000
CY2018Q3 us-gaap Operating Expenses
OperatingExpenses
34366000
CY2018Q4 us-gaap Operating Expenses
OperatingExpenses
54188000
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-41529000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-44142000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-33951000
CY2018Q4 us-gaap Net Income Loss
NetIncomeLoss
-53860000
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2018Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.59
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.43
CY2018Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68

Files In Submission

Name View Source Status
0001558370-20-001897-index-headers.html Edgar Link pending
0001558370-20-001897-index.html Edgar Link pending
0001558370-20-001897.txt Edgar Link pending
0001558370-20-001897-xbrl.zip Edgar Link pending
ex-21d1.htm Edgar Link pending
ex-23d1.htm Edgar Link pending
ex-31d1.htm Edgar Link pending
ex-31d2.htm Edgar Link pending
ex-32d1.htm Edgar Link pending
ex-32d2.htm Edgar Link pending
ex-4d5.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tmb-20191231.xsd Edgar Link pending
tmb-20191231x10k248225.htm Edgar Link pending
tmb-20191231x10k248225003.jpg Edgar Link pending
tmb-20191231x10k248225_htm.xml Edgar Link completed
tmb-20191231_cal.xml Edgar Link unprocessable
tmb-20191231_def.xml Edgar Link unprocessable
tmb-20191231_lab.xml Edgar Link unprocessable
tmb-20191231_pre.xml Edgar Link unprocessable